Recursion Pharmaceuticals, Inc.

RXRX

$3.44

+1.78%

N/A+$0.06

Healthcare

Biotechnology

NASDAQ

Negociación activa

Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery ...

Transacciones de insiders de RXRX

Compras (A)

Since Jun 17, 2026

Ventas (D)

Since Jun 17, 2026

Acciones mensuales compradas/vendidas con tendencia del precio de cierre (fuente diaria compartida)

Resumen de trading de insiders

Fecha	Ejecutivo	Cargo	Valor	Lado	Acciones	Precio
Sep 1, 2026	Borgeson Blake	director	Class A Common Stock	D	30,000	$3.34
Aug 17, 2026	Khan Najat	director, officer: CEO and President	Class A Common Stock	D	80,498	$3.16
Aug 17, 2026	Hallett David	officer: Chief Scientific Officer	Class A Common Stock	D	26,657	$3.16
Aug 17, 2026	Taylor Ben R	officer: Chief Financial Officer	Class A Common Stock	D	25,018	$3.16
Aug 4, 2026	Borgeson Blake	director	Class A Common Stock	D	30,000	$3.25

Resumen de trading de insiders

Compras (A)

Ventas (D)

Acciones compradas totales

97,280

Acciones vendidas totales

236,136

Actividad mensual de insiders

Acciones mensuales compradas/vendidas con tendencia del precio de cierre (fuente diaria compartida)

Por cargo - Acciones

Eje X: acciones, ordenado por acciones totales desc.

Por cargo - Conteos

Eje X: conteos, ordenado por conteos A+D desc.

Personas clave: actividad de compra/venta y precio

Khan Najat

director, officer: CEO and President • 1 transacciones

Borgeson Blake

director • 4 transacciones

Hallett David

officer: Chief Scientific Officer • 1 transacciones

Taylor Ben R

officer: Chief Financial Officer • 1 transacciones

Tabla de transacciones

Fecha	Ejecutivo	Cargo	Valor	Lado	Acciones	Precio	Valor
Sep 1, 2026	Borgeson Blake	director	Class A Common Stock	D	30,000	$3.34	$100,200.00
Aug 17, 2026	Khan Najat	director, officer: CEO and President	Class A Common Stock	D	80,498	$3.16	$254,373.68
Aug 17, 2026	Hallett David	officer: Chief Scientific Officer	Class A Common Stock	D	26,657	$3.16	$84,236.12
Aug 17, 2026	Taylor Ben R	officer: Chief Financial Officer	Class A Common Stock	D	25,018	$3.16	$79,056.88
Aug 4, 2026	Borgeson Blake	director	Class A Common Stock	D	30,000	$3.25	$97,500.00
Jul 7, 2026	Borgeson Blake	director	Class A Common Stock	D	40,000	$3.96	$158,500.00
Jul 1, 2026	Dar Zavain	director	Class A Common Stock	A	5,109	—	—
Jul 1, 2026	Li Dean Y	director	Class A Common Stock	A	3,747	—	—
Jun 18, 2026	Bumpus Namandje	director	Class A Common Stock	D	3,963	$3.18	$12,602.34
Jun 17, 2026	Borgeson Blake	director	Class A Common Stock	A	88,424	—	—

Supply Chain de RXRX

RELATIONS

Upstream

NVIDIA CorporationNASDAQ:NVDA Google Cloud (Alphabet Inc.)NASDAQ:GOOGL Molecular Devices (Danaher Corporation subsidiary)NYSE:DHR Beckman Coulter (Danaher Corporation subsidiary)NYSE:DHR Tempus AI, Inc.NASDAQ:TEMHelix (Helix OpCo LLC)Splunk (Cisco Systems, Inc.)NASDAQ:CSCO Thermo Fisher Scientific Inc.NYSE:TMO Taiwan Semiconductor Manufacturing Company (TSMC)NYSE:TSM

Downstream

Roche Holding AG / GenentechSIX:ROGSanofi S.A.NASDAQ:SNYBayer AGXTRA:BAYNMerck KGaAXTRA:MRK

Proxies

Schrödinger, Inc.NASDAQ:SDGR Relay Therapeutics, Inc.NASDAQ:RLAYExscientia plc (former)UnconfirmedAbCellera Biologics, Inc.NASDAQ:ABCL

Sobre nosotrosPolítica de privacidadTérminos de servicioAviso legalDirectorio de accionesETFÍndicesCarteras 13FPrecios objetivoHerramientas gratuitasMapa tecnológicoÚnete a nuestro Slack

Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal